Antigentic peptides and process for their preparation
US4833072A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 13, 1986 |
| Grant date | May 23, 1989 |
| Priority date | — |
| Expiry date | Nov 13, 2006 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/221
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to antigenic peptides of the formula EQU H--Val--X--Y FORMULA I wherein X is a polypeptide residue selected from the group consisting of: PA1 Val-Pro-Arg-Arg-Lys-Ala-Lys-Ile; PA1 Ser-Gly-Lys-Ala-Arg-Gly-Trp-Phe; PA1 Tyr-Tyr-Arg-Asp-Ser-Arg-Ash-Pro-Leu; PA1 Phe-Ile-His-Asn-Phe-Lys-Arg-Lys-Gly; PA1 Ser-Ile-Glu-Trp-Arg-Lys-Lys-Arg-Tyr-Ser; and PA1 Leu-His-Thr-Gly-Glu-Arg-Asp-Trp-His-Leu-Gly, and Y is a hydroxyl group or an amino group. The invention also relates to a method of preparing these peptides. These novel peptides exhibit useful antigenic properties, with respect to Human Immunodeficiency Virus (HIV), formerly known as Human T-cell Lymphotropic Type-III Virus (HTLV-III). Human Immunodeficiency Virus is associated with the diseases known as Acquired Immune Deficiency Syndrome (AIDS) and Aids Related Complex (ARC). The present antigenic peptides are useful for the detection of antibodies active against HIV and are suitable for use as diagnostic agents. The antigenic peptides of the invention have been shown to induce an in vivo immune response in animals, and the in vitro production of monoclonal antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.